Improving the therapeutic ratio in hodgkin lymphoma through the use of proton therapy

ONCOLOGY (United States)

Volumn 26, Issue 5, 2012, Pages

  Hoppe, Bradford S ^a   Flampouri, Stella ^a   Lynch, James ^a   Slayton, William ^a   Zaiden, Robert ^b   Li, Zuofeng ^a   Mendenhall, Nancy P ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED RADIOTHERAPY; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM CANCER; ESOPHAGITIS; EXTENDED FIELD RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEART INFARCTION; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; INVOLVED FIELD RADIOTHERAPY; INVOLVED NODE RADIOTHERAPY; LEUKOPENIA; LUNG CANCER; MANTLE FIELD RADIOTHERAPY; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OSTEOSARCOMA; PHARYNGITIS; PROTON THERAPY; RADIATION DOSE; RADIATION FIELD; RADIATION RESPONSE; REVIEW; SECOND CANCER; STOMACH CANCER; THROMBOCYTOPENIA; THYROID CANCER; TISSUE SPECIFICITY; VALVULAR HEART DISEASE;

EID: 84874595032     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Mendenhall NP, Rodrigue LL, Moore-Higgs GJ, et al. The optimal dose of radiation in Hodgkins disease: an analysis of clinical and treatment factors affecting in-field disease control. Int J Radiat Oncol Biol Phys. 1999;44:551-61.
2. Thomas J, Ferme C, Noordijk EM, et al. Six cycles of ABVD + IF-RT vs four cycles of ABVD + IF-RT vs four cycles of BEACOPP + IF-RT in unfavourable supradiaphragmatic clinical stages I-II Hodgkins lymphoma: the EORTC-GELA H9-U randomized clinical trial (20982) in 808 patients. Eur J Haematol. 2004;73: A-E12, 40.
3. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-82.
4. Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117:5314-20.
5. Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 Trial. Haematologica. 2010;95:473.
6. Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res. 2010;174:741-52.
7. Macdonald DA, Ding K, Gospodarowicz MK, et al. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol. 2007; 18:1680-4.
8. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkins lymphoma. N Engl J Med. 2012; 366:399-408.
9. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkins disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101-8.
10. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkins lymphoma. J Clin Oncol. 2007;25:1489-97.
11. Smith J. Postradiation sarcoma of bone in Hodgkin disease. Skeletal Radiol. 1987;16:524-32.
12. De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood. 2009;113:3679-81.
13. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003; 290:465-75.
14. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkins disease. J Natl Cancer Inst. 2002;94:182-92.
15. van den Belt-Dusebout AW, Aleman BM, Besseling G, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys. 2009;75:1420-9.
16. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.
17. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28:1308-15.
18. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkins lymphoma: results of the HD8 trial of the German Hodgkins Lymphoma Study Group. J Clin Oncol. 2003;21:3601-8.
19. Klimm B, Eich HT, Haverkamp H, et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkins lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol. 2007;18:357-63.
20. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkins lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17:1749-60.
21. Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012 Jan 21. [Epub ahead of print]
22. Weber DC, Johanson S, Peguret N, et al. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage Hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys. 2011; 81:490-7.
23. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkins lymphoma. N Engl J Med. 2010;363:640-52.
24. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkins lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199-206.
25. Goodman KA, Toner S, Hunt M, et al. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys. 2005; 62:198-206.
26. Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys. 2006;64:218-26.
27. Koeck J, Abo-Madyan Y, Lohr F, et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83: 268-76.
28. Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2011;80:199-205.
29. Archambeau JO, Bennett GW, Levine GS, et al. Proton radiation therapy. Radiology. 1974;110:445-57.
30. Hoppe BS, Flampouri S, Su Z, et al. Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys. 2012;83:260-7.
31. Li J, Dabaja B, Reed V, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys. 2011;81:167-74.
32. Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012; in press.
33. Andolino DL, Hoene T, Xiao L, et al. Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkins lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys. 2011;81:e667-71.
34. Hoppe BS, Flampouri S, Li Z, Mendenhall NP. Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma. Leuk Lymphoma. 2010;51:1559-62.
35. Figura NB, Flampouri S, Hopper K, et al. Consolidative proton therapy following high-dose chemotherapy and autologous stem cell transplant in an adolescent with relapsed Hodgkin lymphoma. J Adolesc Young Adult Oncol. 2011;1:103-06.
36. Simone CB, 2nd, Kramer K, OMeara WP, et al. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys. 2012;82:242-9.
37. Hoppe BS, Mamalui-Hunter M, Mendenhall NP, et al. Improving the therapeutic ratio by using proton therapy in patients with stage I or II seminoma. Am J Clin Oncol. 2011 Nov 29. [Epub ahead of print]
38. Chung CS, Keating N, Yock T, Tarbell NJ. Comparative analysis of second malignancy risk in patients treated with proton therapy versus conventional photon therapy. Int J Radiat Oncol Biol Phys. 2008;72:S8.